Cantor Fitzgerald Cuts AbbVie Target Price, Anticipates Weak Pharma Catalyst

Cantor Fitzgerald has lowered its target price for AbbVie (ABBV) and cautioned that the company’s upcoming catalysts may be weak. The analyst team revised the target price after assessing potential short‑term catalysts that could impact AbbVie’s financial performance. The decision signals a reassessment of the company within market expectations and valuation frameworks. The new target price is set lower than the previous level, establishing a more conservative price range for AbbVie’s shares. This adjustment encourages investors to adopt a cautious stance regarding the company’s future growth potential and profitability expectations. Cantor Fitzgerald’s update underscores the need to re‑evaluate AbbVie in light of competitive dynamics within the sector and macroeconomic factors. Investors should consider such analyses in line with their risk profiles when forming decisions. This is not investment advice.